Mivobulin

Drug Profile

Mivobulin

Alternative Names: CI 980; Mivobulin isethionate; NSC 370147; NSC 613862; NSC 635370; PD 13114154

Latest Information Update: 20 Jul 2011

Price : $50

At a glance

  • Originator Southern Research Institute
  • Class Antineoplastics
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Arrhythmias; Glioma; Malignant melanoma; Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 20 Jul 2011 Discontinued - Phase-II for Solid tumours in USA (IV)
  • 20 Jul 2011 Discontinued - Phase-II for Small cell lung cancer in USA (IV)
  • 20 Jul 2011 Discontinued - Phase-II for Prostate cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top